{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:17:16Z","timestamp":1784859436610,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["seminarsinnuclearmedicine.com","patient-research.elsevier.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1053\/j.semnuclmed.2014.03.007","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T13:23:25Z","timestamp":1399987405000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Dosimetry for Radiopharmaceutical Therapy"],"prefix":"10.1053","volume":"44","author":[{"given":"George","family":"Sgouros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib1","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2014.03.007_bib2","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2014.03.007_bib3","first-page":"62S","article-title":"Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs","volume":"46","author":"Kwekkeboom","year":"2005","journal-title":"J Nucl Med."},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.03.007_bib4","first-page":"347","article-title":"Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues","volume":"14","author":"Bodei","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.03.007_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nm0311-286","article-title":"Targeting RAF: Trials and tribulations","volume":"17","author":"Downward","year":"2011","journal-title":"Nat Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2014.03.007_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4161\/cbt.11.9.15045","article-title":"Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications","volume":"11","author":"Garrett","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2014.03.007_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10428194.2010.546912","article-title":"Chronic myeloid leukemia cells refractory\/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state","volume":"52","author":"Skorski","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5531","key":"10.1053\/j.semnuclmed.2014.03.007_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib9","unstructured":"Lewington VJ, Parker C, Hindorf C, et al.: Alpharadin: A novel, targeted approach for treatment of bone metastases from CRPC-calculated alpha-particle dosimetry compared to a favorable clinical safety profile. ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2010."},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.03.007_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet no. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.03.007_bib11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2967\/jnumed.106.038000","article-title":"Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry","volume":"48","author":"Prideaux","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib12","series-title":"Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine","first-page":"249","article-title":"The three-dimensional internal dosimetry software package, 3D-ID","author":"Sgouros","year":"2002"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib13","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.2967\/jnumed.110.077149","article-title":"Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size","volume":"51","author":"Dieudonne","year":"2010","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.03.007_bib14","first-page":"11S","article-title":"MIRD pamphlet no. 17: The dosimetry of nonuniform activity distributions\u2014Radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee","volume":"40","author":"Bolch","year":"1999","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.03.007_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2967\/jnumed.112.105825","article-title":"Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: Comparison between dose kernel convolution and direct Monte Carlo methods","volume":"54","author":"Dieudonne","year":"2013","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.03.007_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1118\/1.598063","article-title":"Reporting and analyzing dose distributions: A concept of equivalent uniform dose","volume":"24","author":"Niemierko","year":"1997","journal-title":"Med Phys"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.03.007_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0360-3016(91)90173-2","article-title":"Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations","volume":"21","author":"Kutcher","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 3","key":"10.1053\/j.semnuclmed.2014.03.007_bib18","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative analyses of normal tissue effects in the clinic (QUANTEC): An introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"690","key":"10.1053\/j.semnuclmed.2014.03.007_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1259\/0007-1285-58-690-515","article-title":"The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy","volume":"58","author":"Dale","year":"1985","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.03.007_bib20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1088\/0031-9155\/43\/4\/014","article-title":"Fast implementations of reconstruction-based scatter compensation in fully 3D SPECT image reconstruction","volume":"43","author":"Kadrmas","year":"1998","journal-title":"Phys Med Biol"},{"issue":"17","key":"10.1053\/j.semnuclmed.2014.03.007_bib21","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1088\/0031-9155\/50\/17\/018","article-title":"A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT","volume":"50","author":"He","year":"2005","journal-title":"Phys Med Biol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.03.007_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1109\/42.363108","article-title":"Accelerated image reconstruction using ordered subsets of projection data","volume":"13","author":"Hudson","year":"1994","journal-title":"IEEE Trans Med Imaging"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.03.007_bib23","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1088\/0031-9155\/55\/8\/016","article-title":"Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging","volume":"55","author":"Jentzen","year":"2010","journal-title":"Phys Med Biol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.03.007_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00259-007-0554-7","article-title":"Iodine-124 PET dosimetry in differentiated thyroid cancer: Recovery coefficient in 2D and 3D modes for PET(\/CT) systems","volume":"35","author":"Jentzen","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.03.007_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2967\/jnumed.111.096677","article-title":"Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma","volume":"53","author":"Senthamizhchelvan","year":"2012","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.03.007_bib26","first-page":"79","article-title":"Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET","volume":"57","author":"Hobbs","year":"2013","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib27","article-title":"The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103","year":"2007","journal-title":"Ann ICRP 37(2-4)"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib28","article-title":"Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (WR): ICRP Publication 92","year":"2003","journal-title":"Ann ICRP 33 (4)"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib29","series-title":"Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2","year":"2006"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib30","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with Y-90-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2014.03.007_bib31","first-page":"1113","article-title":"MIRD pamphlet no 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney","volume":"44","author":"Bouchet","year":"2003","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.03.007_bib32","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response\u2014Implications for radionuclide therapy","volume":"49","author":"Wessels","year":"2008","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.03.007_bib33","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2967\/jnumed.109.066738","article-title":"124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: Real-time treatment planning and methodologic comparison","volume":"50","author":"Hobbs","year":"2009","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib34","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1118\/1.4752213","article-title":"Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy","volume":"39","author":"Baechler","year":"2012","journal-title":"Med Phys"},{"issue":"4","key":"10.1053\/j.semnuclmed.2014.03.007_bib35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.ijrobp.2010.08.022","article-title":"A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy","volume":"80","author":"Hobbs","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1053\/j.semnuclmed.2014.03.007_bib36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2967\/jnumed.112.117952","article-title":"Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma","volume":"54","author":"Hobbs","year":"2013","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.03.007_bib37","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00259-009-1333-4","article-title":"A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin)","volume":"37","author":"Pacilio","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.03.007_bib38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/cbr.2007.302","article-title":"Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: Possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results","volume":"22","author":"Chiesa","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.03.007_bib39","first-page":"546","article-title":"Individualized dosimetry in the management of metastatic differentiated thyroid cancer","volume":"53","author":"Chiesa","year":"2009","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.03.007_bib40","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00259-012-2197-6","article-title":"3D dosimetry in patients with early breast cancer undergoing intraoperative avidination for radionuclide therapy (IART) combined with external beam radiation therapy","volume":"39","author":"Ferrari","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2014.03.007_bib41","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2967\/jnumed.111.095232","article-title":"Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres","volume":"52","author":"Dieudonne","year":"2011","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.03.007_bib42","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00259-008-0857-3","article-title":"Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment","volume":"35","author":"Cremonesi","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2014.03.007_bib43","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","article-title":"Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: Radiobiologic considerations","volume":"51","author":"Strigari","year":"2010","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.03.007_bib44","first-page":"168","article-title":"Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: The experience of the National Tumor Institute of Milan","volume":"55","author":"Chiesa","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib45","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1007\/s00259-009-1210-1","article-title":"Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT","volume":"36","author":"Lhommel","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"21","key":"10.1053\/j.semnuclmed.2014.03.007_bib46","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1088\/0031-9155\/56\/21\/001","article-title":"Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy","volume":"56","author":"van Elmbt","year":"2011","journal-title":"Phys Med Biol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.03.007_bib47","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1118\/1.3700174","article-title":"Development and evaluation of an improved quantitative (90)Y bremsstrahlung SPECT method","volume":"39","author":"Rong","year":"2012","journal-title":"Med Phys"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.03.007_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2967\/jnumed.111.094235","article-title":"Dosimetry based on 99mTc-macroaggregated albumin SPECT\/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: Preliminary results","volume":"53","author":"Garin","year":"2012","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.03.007_bib49","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2967\/jnumed.112.117614","article-title":"99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization","volume":"54","author":"Wondergem","year":"2013","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2014.03.007_bib50","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2967\/jnumed.113.123257","article-title":"Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT","volume":"54","author":"Lam","year":"2013","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.03.007_bib51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1874471011104030261","article-title":"Modelling and dosimetry for alpha-particle therapy","volume":"4","author":"Sgouros","year":"2011","journal-title":"Curr Radiopharm"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib52","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1039\/b704726f","article-title":"Targeted alpha therapy: Past, present, future?","volume":"43","author":"Brechbiel","year":"2007","journal-title":"Dalton Trans"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib53","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-13-0108","article-title":"Targeting aberrant DNA double strand break repair in triple negative breast cancer with alpha particle emitter radiolabeled anti-EGFR antibody","volume":"12","author":"Song","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib54","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2967\/jnumed.110.077578","article-title":"The alpha-camera: A quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles","volume":"51","author":"Back","year":"2010","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.03.007_bib55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet no. 21: A generalized schema for radiopharmaceutical dosimetry\u2014Standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2014.03.007_bib56","first-page":"37S","article-title":"MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib57","series-title":"\u201cS,\u201d Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11","author":"Snyder","year":"1975"},{"issue":"13","key":"10.1053\/j.semnuclmed.2014.03.007_bib58","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1088\/0031-9155\/57\/13\/4403","article-title":"A nephron-based model of the kidneys for macro-to-micro alpha-particle dosimetry","volume":"57","author":"Hobbs","year":"2012","journal-title":"Phys Med Biol"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib59","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1088\/0031-9155\/57\/10\/3207","article-title":"A bone marrow toxicity model for (223)Ra alpha-emitter radiopharmaceutical therapy","volume":"57","author":"Hobbs","year":"2012","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.03.007_bib60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2967\/jnumed.111.095133","article-title":"A small-scale anatomic model for testicular radiation dosimetry for radionuclides localized in the human testes","volume":"53","author":"Larsson","year":"2011","journal-title":"J Nucl Med."},{"issue":"23","key":"10.1053\/j.semnuclmed.2014.03.007_bib61","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","article-title":"Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: Comparing efficacy with 213Bi and 90Y","volume":"69","author":"Song","year":"2009","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2014.03.007_bib62","first-page":"792","article-title":"Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images","volume":"44","author":"Akabani","year":"2003","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.03.007_bib63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2307\/3579736","article-title":"Microdosimetry of astatine-211 using histological images: Application to bone marrow","volume":"148","author":"Akabani","year":"1997","journal-title":"Radiat Res"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.03.007_bib64","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1667\/RR1536.1","article-title":"Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results","volume":"171","author":"Chouin","year":"2009","journal-title":"Radiat Res"},{"issue":"6","key":"10.1053\/j.semnuclmed.2014.03.007_bib65","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1667\/RR1371.1","article-title":"Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model","volume":"171","author":"Chouin","year":"2009","journal-title":"Radiat Res"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib66","series-title":"Therapeutic Applications of Monte Carlo in Nuclear Medicine","first-page":"204","article-title":"Microdosimetry of targeted radionuclides","author":"Roeske","year":"2003"},{"issue":"11","key":"10.1053\/j.semnuclmed.2014.03.007_bib67","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/0360-3016(87)90176-3","article-title":"A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy","volume":"13","author":"Humm","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.03.007_bib68","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"MIRD pamphlet no. 23: Quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2014.03.007_bib69","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.2967\/jnumed.113.122390","article-title":"MIRD pamphlet no. 24: Guidelines for quantitative 131I SPECT in dosimetry applications","volume":"54","author":"Dewaraja","year":"2013","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2014.03.007_bib70","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1088\/0031-9155\/58\/8\/2491","article-title":"Development and validation of RAYDOSE: A Geant4-based application for molecular radiotherapy","volume":"58","author":"Marcatili","year":"2013","journal-title":"Phys Med Biol"},{"issue":"22","key":"10.1053\/j.semnuclmed.2014.03.007_bib71","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1088\/0031-9155\/58\/22\/8099","article-title":"Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images","volume":"58","author":"Botta","year":"2013","journal-title":"Phys Med Biol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.03.007_bib72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/cbr.2005.20.325","article-title":"OEDIPE: A personalized dosimetric tool associating voxel-based models with MCNPX","volume":"20","author":"Chiavassa","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"10.1053\/j.semnuclmed.2014.03.007_bib73","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/108497803321269331","article-title":"RMDP: A dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry","volume":"18","author":"Guy","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2014.03.007_bib74","unstructured":"Health NIo. NIH Director\u2019s Blog. Accessed November 14, 2013"},{"issue":"10","key":"10.1053\/j.semnuclmed.2014.03.007_bib75","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O\u2019Donoghue","year":"1995","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2014.03.007_bib76","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00259-011-2036-1","article-title":"Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail","volume":"39","author":"Savolainen","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1053\/j.semnuclmed.2014.03.007_bib77","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1088\/0031-9155\/57\/13\/4263","article-title":"Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: Assuming similar pharmacokinetics, (125)Sn-(177)Lu is superior to (90)Y-(177)Lu in peptide receptor radiotherapy","volume":"57","author":"Walrand","year":"2012","journal-title":"Phys Med Biol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2014.03.007_bib78","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.nucmedbio.2012.01.011","article-title":"A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: Validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po","volume":"39","author":"Akudugu","year":"2012","journal-title":"Nucl Med Biol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299814000117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299814000117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T10:06:34Z","timestamp":1597831594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299814000117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0001299814000117"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2014.03.007","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosimetry for Radiopharmaceutical Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2014.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}